Pro-protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been studied in patients with acute coronary syndromes only after 2–3 months of treatment with statins and never in the acute phase (first month) of an acute coronary syndrome. Here, PCSK9 is linked to acute coronary syndrome.